Pathstone Family Office’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
Other funds holding ALNY
Pathstone Family Office's ALNY Position: Q3 2023 in Review
Pathstone Family Office opened a new position in Alnylam Pharmaceuticals (ALNY) in Q3 2023: 1,240 shares worth $220K. The stake represents ﹤0.01% of the portfolio and ranks #1454 among its holdings. This is a return to the name: Pathstone Family Office previously reported a position in ALNY as recently as Q3 2014.
Pathstone Family Office first reported a position in ALNY in Q3 2013 and has held it in 4 quarters since. 453 funds tracked by Wall St. Rank hold ALNY as of Q3 2023.
- Pathstone Family Office held 1,240 shares of Alnylam Pharmaceuticals worth $220K as of Q3 2023.
- Alnylam Pharmaceuticals was a new Pathstone Family Office position in Q3 2023.
- Alnylam Pharmaceuticals made up ﹤0.01% of Pathstone Family Office's portfolio in Q3 2023, its #1454 holding.
- Pathstone Family Office first reported a position in Alnylam Pharmaceuticals in Q3 2013 and has held it in 4 quarters since.
- 453 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2023.
Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.